SEMA-NASH

  • What's involved: Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial
  • Take part: Open
  • Principal Investigator: Professor Stephen Ryder
Research Theme | Gastrointestinal & Liver | Open Trials

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.

A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial.

What's involved

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial

Principal Investigator

Professor Stephen Ryder

Take part

Open
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute